SCHEMBL24004359

SCHEMBL24004359

CC(C)OC1OC(CO)C(OC(C)(C)C)C(O)C1O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ MAPT P10636 1/20 0.42
▸ TYR P14679 6/20 0.40
▸ AMY1A P0DUB6 1/20 0.34
▸ CA1 P00915 1/20 0.34
▸ CA2 P00918 1/20 0.34
▸ CA9 Q16790 1/20 0.34
▸ PRKD3 O94806 1/20 0.34
▸ PRKCG P05129 1/20 0.34
▸ PRKCB P05771 1/20 0.34
▸ PRKCA P17252 1/20 0.34
▸ PRKCH P24723 1/20 0.34
▸ PRKCI P41743 1/20 0.34
▸ PRKCE Q02156 1/20 0.34
▸ PRKCQ Q04759 1/20 0.34
▸ PRKCZ Q05513 1/20 0.34
▸ PRKCD Q05655 1/20 0.34
▸ PRKD1 Q15139 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ THRB P10828 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17531088 0.94 TYR (0.47) L3MBTL1MAPTTYRAMY1AALDH1A1
SCHEMBL17298260 0.88 TYR (0.42) L3MBTL1MAPTTYRAMY1ALGALS8
SCHEMBL13126159 0.85 TYR (0.41) L3MBTL1MAPTTYRAMY1ACA1
SCHEMBL24004413 0.85 L3MBTL1 (0.53) L3MBTL1MAPTTYRAMY1ALGALS8
SCHEMBL22224178 0.85 TYR (0.41) L3MBTL1MAPTTYRAMY1ACA1
SCHEMBL24004411 0.85 L3MBTL1 (0.53) L3MBTL1MAPTTYRAMY1ALGALS8
SCHEMBL13034058 0.85 L3MBTL1 (0.53) L3MBTL1MAPTTYRAMY1ALGALS8
SCHEMBL13713719 0.85 TYR (0.41) L3MBTL1MAPTTYRAMY1ACA1
SCHEMBL15317129 0.85 SLC6A2 (0.40) L3MBTL1MAPTTYRAMY1ALGALS8
SCHEMBL13716367 0.83 AMY2A (0.45) L3MBTL1TYRAMY1ACA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210347826-A1 CYCLIC PEPTIDE COMPOUNDS AND METHODS OF USE THEREOF MODULATION THERAPEUTICS, INC. 2021-11-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210347826-A1 CYCLIC PEPTIDE COMPOUNDS AND METHODS OF USE THEREOF VIP, IAPP, SCTR L3MBTL1 531/4885MAPT 4775/4885TYR 1451/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback